KR101637973B1 - Composition for combating oxidation and alleviating detrimental effects on skin caused by asian dust - Google Patents
Composition for combating oxidation and alleviating detrimental effects on skin caused by asian dust Download PDFInfo
- Publication number
- KR101637973B1 KR101637973B1 KR1020137016899A KR20137016899A KR101637973B1 KR 101637973 B1 KR101637973 B1 KR 101637973B1 KR 1020137016899 A KR1020137016899 A KR 1020137016899A KR 20137016899 A KR20137016899 A KR 20137016899A KR 101637973 B1 KR101637973 B1 KR 101637973B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- skin
- extract
- expression
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 239000000428 dust Substances 0.000 title claims description 23
- 230000001627 detrimental effect Effects 0.000 title 1
- 230000003647 oxidation Effects 0.000 title 1
- 238000007254 oxidation reaction Methods 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 54
- 230000014509 gene expression Effects 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 13
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 claims abstract description 10
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 claims abstract description 10
- 102000016938 Catalase Human genes 0.000 claims abstract description 9
- 108010053835 Catalase Proteins 0.000 claims abstract description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000001301 oxygen Substances 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- 230000009931 harmful effect Effects 0.000 claims abstract description 7
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims abstract description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims abstract description 4
- 210000003491 skin Anatomy 0.000 claims description 26
- 210000002510 keratinocyte Anatomy 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 11
- 240000002853 Nelumbo nucifera Species 0.000 claims description 10
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 8
- 239000004576 sand Substances 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 240000008397 Ganoderma lucidum Species 0.000 claims description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 2
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000007599 discharging Methods 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 239000000917 skin toxin Substances 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 16
- 108090000790 Enzymes Proteins 0.000 abstract description 16
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 abstract description 9
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 abstract description 8
- 206010040880 Skin irritation Diseases 0.000 abstract description 8
- 101710168651 Thioredoxin 1 Proteins 0.000 abstract description 8
- 231100000475 skin irritation Toxicity 0.000 abstract description 8
- 230000036556 skin irritation Effects 0.000 abstract description 8
- 239000003053 toxin Substances 0.000 abstract description 8
- 231100000765 toxin Toxicity 0.000 abstract description 8
- 101150076311 Prdx1 gene Proteins 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 230000032683 aging Effects 0.000 abstract description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract description 3
- 101001032462 Homo sapiens Glutathione S-transferase theta-1 Proteins 0.000 abstract 1
- 101001014936 Homo sapiens Glutathione peroxidase 1 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 description 10
- 102000055779 human DEFB103A Human genes 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 108010027853 glutathione S-transferase T1 Proteins 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 108010086596 glutathione peroxidase GPX1 Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 6
- 229940116978 human epidermal growth factor Drugs 0.000 description 6
- 229960000890 hydrocortisone Drugs 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 5
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 235000020710 ginseng extract Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229940088592 immunologic factor Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 244000000231 Sesamum indicum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 101710131282 FAD-linked oxidoreductase easE Proteins 0.000 description 1
- 101150115464 GPX1 gene Proteins 0.000 description 1
- 101150111575 GSTT1 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000158723 Melia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000005807 Nelumbo Nutrition 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 101710199728 Oxidoreductase 1 Proteins 0.000 description 1
- 102000007456 Peroxiredoxin Human genes 0.000 description 1
- 102100029139 Peroxiredoxin-1 Human genes 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 새로운 피부자극 완화제로서 고련피 및 연꽃잎 추출물을 함유하는 항산화용 및 황사에 의한 피부 유해영향 완화용 조성물에 관한 것이다.
구체적으로, 본 발명은 고련피 및 연꽃잎 추출물을 함유하여, 독소를 해독하는 효소인 NQO1, 독소를 배출하는 효소인 GSTT1의 발현을 증가시켜 독소를 해독 및 배출하고, 자연면역인자인 피부항균펩타이드 hBD3의 발현을 증가시켜 피부를 보호하며, GPX1, 카탈라아제(catalase), Trx1, Prdx1의 항산화 단백질의 발현을 증가시켜 활성산소의 생성을 억제함으로써 피부 보호 및 노화 억제의 효과를 갖는다.The present invention relates to a composition for alleviating skin harmful effects caused by antioxidants and yellow dusts containing a sprout extract and a soft petal leaf extract as a new skin irritation relieving agent.
Specifically, the present invention relates to a method for producing a skin antimicrobial peptide, which comprises an extract of sprout and soft petal leaf and increases the expression of NQO1, which is an enzyme for detoxifying toxin, and GSTT1, which is an enzyme for releasing toxin, It protects the skin by increasing the expression of hBD3 and increases the expression of antioxidant protein of GPX1, catalase, Trx1, and Prdx1 to inhibit the production of active oxygen, thereby protecting skin and preventing aging.
Description
본 발명은 항산화용 및 황사에 의한 피부 유해영향 완화용 조성물에 관한 것으로, 보다 구체적으로 고련피 및 연꽃잎을 유효성분으로 함유하는 항산화 효과 및 황사에 의한 피부 유해영향 감소 효과를 갖는 조성물에 관한 것이다.More particularly, the present invention relates to a composition having antioxidative effect and antiseptic effect on skin caused by yellow dust and / or soft petal as an active ingredient .
피부는 외부 환경에 직접적으로 노출되는 신체 부위로서, 우리 몸의 중요한 기관들을 보호하는 보호막 역할을 할 뿐만 아니라 수분 증발을 조절하고 외부 감염으로부터 몸을 보호하는 역할을 한다. 하지만, 아무리 외부로부터의 바이러스 침투까지 막아내는 피부일지라도 과도한 자외선이나 오염물질 등에 노출되면 홍반, 부종, 가려움 등의 피부 자극 및 염증 반응을 유발하게 된다. 이러한 환경유해인자에 의한 피부 트러블은 미관상 문제가 될 뿐만 아니라, 세포의 항산화 보호시스템이 감당하지 못할 만큼 증가된 활성산소종은 DNA, 단백질, 지방, 당에 해를 끼치며 세포의 생존, 성장, 분화에 영향을 주고, 세포사멸을 일으키기도 한다. 장기간 계속된 산화적 스트레스는 피부노화와 암, 염증을 일으키게 된다.(Ismail et al., Angiopoietin-1 reduces H(2)O(2)-induced increases in reactive oxygen species and oxidative damage to skin cells.J Invest Dermatol. 130(5):1307-17, 2010)Skin is a part of the body that is directly exposed to the external environment. It acts as a protective layer to protect important organs of our body, as well as controlling water evaporation and protecting the body from external infections. However, even if it prevents skin penetration from the outside, exposure to ultraviolet rays or pollutants causes skin irritation such as erythema, edema, itching, and inflammatory reaction. Skin troubles caused by these harmful environmental factors are not only cosmetic problems but also increased reactive oxygen species that can not be supported by the antioxidant protection system of the cells harm DNA, protein, fat and sugar. And may cause cell death. Long-term oxidative stress causes skin aging, cancer, and inflammation (Ismail et al., Angiopoietin-1 reduces H (2) -induced increases in reactive oxygen species and oxidative damage to skin cells. Invest Dermatol, 130 (5): 1307-17, 2010)
황사는 중국 및 몽고 등의 내륙에 위치한 사막에서 작은 모래나 황토가 부유하여 상층바람을 타고 멀리 수송되어, 지면 가까이 낙하하는 현상이다. 우리나라에서도 매년 봄철이면 황사가 주기적으로 발생한다. 황사는 유기물과 무기물의 복합체로 발생시기와 장소에 따라 물리적 특성과 구성성분이 매우 다양하며, 생물학적으로 영향을 줄 수 있는 금속 성분도 포함하고 있다. 황사 중 크기가 큰 입자들은 주로 발원지나 주변에 머물며, 국내에 유입되는 것들은 대개 지름 10μm 이하의 미세먼지(Particulate matter 10; PM10)이다. 이러한 미세먼지가 흡입 시에 하부기관지 및 폐의 가스-교환부분까지 침착하여 호흡기계에 손상을 일으킬 수 있다고 보고된 바 있다(Yanagisawa et al., Gene expression analysis of murine lungs following pulmonary exposure to asian sand dust particles. Exp Biol Med 232:1109-1118, 2007, Kim et al., Cytotoxicity of yellow sand in lung epithelial cells. J Biosci 28(1):77-81, 2003). 황사의 인체 내 유해성에 대한 연구는 호흡기질환 연구에서 많이 이루어졌는데, 실험용 쥐를 이용한 연구에서 실제 황사발생 시 채취된 황사를 흡입시킨 결과 폐에서 산화스트레스 관련 지표가 상승했다는 동물실험연구가 있다(Naota et al., Pathological Study of Acute Pulmonary Toxicity Induced by Intratracheally Instilled Asian Sand Dust. Toxicol Pathol. 2010 Sep 30. [Epub ahead of print]).Dust is a phenomenon in which small sand or loess is floated in the inland deserts of China and Mongolia, and is transported far away in the upper winds, falling near the ground. In Korea, yellow dust occurs periodically every spring. Dusts are a complex of organic matter and inorganic matter, and their physical characteristics and constituents are very diverse depending on when and where they occur, and they also contain metal components that can biologically affect them. Large dust particles usually stay at the source or periphery, and those that enter the country are mostly particulate matter 10 (PM10) with a diameter of 10 μm or less. It has been reported that such fine dusts may be deposited on the gas-exchange parts of the lower bronchus and lungs during inhalation, causing damage to the respiratory system (Yanagisawa et al., Gene expression analysis of murine lungs following pulmonary exposure to asian sand dust J Biosci 28 (1): 77-81, 2003). Studies on the harmfulness of yellow dust in the human body have been conducted in many studies on respiratory diseases. An experimental study of experimental mice showed that inhaling yellow dust collected during the actual dusting of yellow dust resulted in elevation of oxidative stress-related indicators in the lungs (Naota et al., Pathological Study of Acute Pulmonary Toxicity Induced by Intratracheally Instilled Asian Sand Dust. Toxicol Pathol. 2010 Sep 30. [Epub ahead of print]).
임상적으로 황사바람이 직접 피부에 닿으면 알레르기 반응을 일으켜 접촉성 피부염이 발생하기 쉬우며, 또 건조하고 세찬 황사바람은 피부의 수분을 앗아가 피부건조증, 각질, 가려움증, 황사여드름 및 아토피 등을 유발한다고 알려져 있으며, 최근 황사에 의한 피부유해영향에 관하여 각질형성세포에서 전염증인자인 사이토카인 인터루킨 6, 인터루킨 8을 증가시키는 것이 최초로 보고되었다 (Choi et al., Asian dust storm particles induce a broad toxicological transcriptional program in human epidermal keratinocytes. Toxicol Lett. 15;200(1-2):92-9. 2010).Clinically, when the yellow wind directly touches the skin, it causes an allergic reaction, and it is easy for contact dermatitis to occur. Also, dry and dazzling yellowish winds take away the moisture of the skin and cause dry skin, keratin, itching, dust acne and atopy Recently, it has been reported that increase of
피부의 최외각층에 존재하는 각질세포(각질형성세포, Keratinocyte)는 섬유아세포, 내피세포 및 진피세포에 주로 있는 면역세포들과 상호작용하여 피부자극반응의 개시, 조정, 조절에 중요한 역할을 한다. 피하의 염증반응과 관련하여 피부자극은 가장 일반적인 유해효과이며 임상적으로 접촉성 피부염의 70%는 피부자극으로 설명될 수 있다. 홍반, 부종, 균열, 수분손실, 표피탈락, 간지럼증 및 통증은 자극성 또는 알러지성 접촉성 피부염의 대표적 증상들이다. 이것은 세포의 항상성에 이상이 오고 염증반응이 일어나 생기는 증상들이다. 황사와 관련에 의한 피부자극의 연구는 전세계적으로 거의 되어 있지 않으나, 황사의 빈도수가 늘어남에 따라 황사에 의한 피부자극을 예방하거나 치료하는 천연외용제를 개발하는 것이 매우 필요한 실정이었다.The keratinocytes (keratinocyte) present in the outermost layers of the skin play an important role in the initiation, regulation and regulation of the skin irritation reaction by interacting with immune cells mainly in fibroblasts, endothelial cells and dermis cells. Skin irritation is the most common adverse effect associated with subcutaneous inflammation, and clinically 70% of contact dermatitis can be explained by skin irritation. Erythema, edema, cracks, water loss, epidermal dysplasia, tickling and pain are typical symptoms of irritable or allergic contact dermatitis. This is a symptom of an abnormality in the homeostasis of the cell and an inflammatory reaction. Although research on skin irritation associated with yellow dust is rarely performed globally, it has been very necessary to develop a natural external preparation for preventing or treating skin irritation caused by yellow dust as the frequency of yellow dust increases.
본 발명은 새로운 피부자극 완화제로서 고련피 및 연꽃잎 추출물을 함유하여, 황사에 의한 피부유해영향을 감소시키고 항산화 효과를 갖는 조성물을 제공하는 것을 그 목적으로 한다.It is an object of the present invention to provide a novel skin irritation mitigating agent containing a sprout extract and a soft petal leaf extract to reduce skin harmful effects caused by yellow sand and to have an antioxidative effect.
상기 목적을 해결하기 위하여, 본 발명은 고련피 추출물을 유효성분으로 함유하는 항산화용 조성물을 제공한다.In order to solve the above-mentioned object, the present invention provides an antioxidative composition comprising an extract of Sophora edulis as an active ingredient.
본 발명의 일실시예에 있어서, 상기 조성물은 연꽃잎 추출물을 더 함유할 수 있다.In one embodiment of the present invention, the composition may further comprise a lotus leaf extract.
본 발명의 일실시예에 있어서, 상기 조성물은 활성산소종 생성을 억제함 또는 항산화 단백질 유전자의 발현을 증가시킴을 특징으로 할 수 있다.In one embodiment of the present invention, the composition may be characterized by inhibiting the production of reactive oxygen species or increasing the expression of an antioxidant protein gene.
또한, 본 발명은 고련피 추출물 및 연꽃잎 추출물을 유효성분으로 함유하는 황사에 의한 피부 유해영향 완화용 조성물을 제공한다.The present invention also provides a composition for alleviating skin harmful effects caused by yellow sand containing an extract of plum blossom and a lotus leaf extract as an active ingredient.
본 발명의 일실시예에 있어서, 상기 조성물은 GST, NQO1 또는 hBD3의 발현을 증가시킴을 특징으로 할 수 있다.In one embodiment of the present invention, the composition may be characterized by increasing the expression of GST, NQO1 or hBD3.
본 발명은 독소를 해독하는 효소인 NQO1, 독소를 배출하는 효소인 GSTT1의 발현을 증가시켜 독소를 해독 및 배출하고, 자연면역인자인 피부항균펩타이드 hBD3의 발현을 증가시켜 피부를 보호하며, GPX1, 카탈라아제(catalase), Trx1, Prdx1의 항산화 단백질의 발현을 증가시켜 활성산소의 생성을 억제함으로써 피부를 보호하고 노화를 억제하는 효과가 있어, 이 조성물을 황사로 인한 트러블 방지, 피부보호 및 노화의 치료 및 예방의 약학 또는 화장품 조성물에 적용할 수 있다.The present invention increases the expression of NQO1, an enzyme that cleans toxins, and GSTT1, an enzyme that excretes toxins, to detoxify and release toxins, protect skin by increasing the expression of the skin antimicrobial peptide hBD3, a natural immune factor, It increases the expression of antioxidant proteins of catalase, Trx1 and Prdx1, thereby inhibiting the production of active oxygen, thereby protecting skin and inhibiting aging. This composition is used for prevention of trouble caused by yellow dust, treatment of skin protection and aging And prophylactic pharmaceutical or cosmetic compositions.
도 1은 본 발명의 일실시예에 따른 조성물을 사람정상각질피부세포에 처리한 경우 활성산소의 생성량을 나타낸 그래프이다.
도 2 내지 4는 본 발명의 일실시예에 따른 조성물을 사람정상각질피부세포에 처리한 경우 각각 NQO1(도 2), hBD3(도 3), GSTT1(도 4)의 발현량을 확인한 중합효소연쇄반응(RT-PCR) 분석 결과를 나타낸 그래프이다.
도 5는 본 발명의 일실시예에 따른 조성물을 사람정상각질피부세포에 처리한 경우 GPX1, 카탈라아제(catalase), Trx1, Prdx1의 발현량을 확인한 중합효소연쇄반응(RT-PCR) 분석 결과를 나타낸 그래프이다.FIG. 1 is a graph showing the amount of active oxygen produced when a composition according to an embodiment of the present invention is treated on human normal cornea skin cells.
FIGS. 2 to 4 are graphs showing the expression levels of NQO1 (FIG. 2), hBD3 (FIG. 3) and GSTT1 (FIG. 4) when the composition according to an embodiment of the present invention is treated with human normal exocrine skin cells, Reaction (RT-PCR) analysis results.
FIG. 5 shows the results of RT-PCR analysis of GPX1, catalase, Trx1, and Prdx1 expression levels when the composition according to an embodiment of the present invention was treated with human normal horny skin cells Graph.
이하에서는, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 본 발명을 용이하게 실시할 수 있도록 하기 위하여, 본 발명의 바람직한 실시예들에 관하여 도면을 참조하여 상세히 설명하기로 한다.Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings, so that those skilled in the art can easily carry out the present invention.
본 발명은 고련피 추출물을 유효성분으로 함유하는 항산화용 조성물을 제공한다.The present invention provides a composition for antioxidant containing an extract of spinach as an active ingredient.
고련피는 멀구슬나무과의 멀구슬나무(Melia azedarach L. var. japonica Makino의 학명으로 불리기도 함)의 수피 또는 근피를 말하며, 회충, 요충을 제거하고 풍진(風疹)과 개선(疥癬)을 치료한다. 피부습진에도 활용하며 이뇨와 해열작용이 있다. 약리작용으로 촌충구제약 및 회중 등의 장내기생충제거, 트리코모나스질염에 효과가 있음이 보고되었으나, 항산화 효과에 대해서는 보고된 바가 없다. 생김새는 구부러진 반관상 또는 관상으로 바깥면은 회갈색이고 세로로 길게 찢어진 무늬와 가로로 된 피목이 있으며, 코르크층을 벗긴 것은 적갈색이다. 꺾은 면은 황백색으로 섬유성이며 질은 단단하나 꺾이기 쉽다. 이 약은 피목이 많은 어린 나무껍질이 좋다. 다른 이름으로 고련근피, 련피, 련근목피, 금령자(金鈴子) 등이 있다. Melia ( bellflower) azedarach L. var. It is called bark or muscle of japonica Makino. It removes roundworms, caterpillars, and treats rubella and scabies. It is also used for skin eczema and has diuretic and antipyretic action. It has been reported that pharmacological action is effective in eliminating intestinal parasites such as tapeworms and condoms and trichomoniasis, but no antioxidant effect has been reported. It has a semi-tubular or tubular shape with a gray color on the outside, a longitudinally torn pattern and a transverse shrub, and a cork layer with a reddish brown color. The folded surface is yellowish white and fibrous, the quality is hard but it is easy to break. This medicine is good for young tree bark with many shrubs. Other names include Pusan, Pusan, Sukmyun, and Banzuko.
본 발명의 조성물은 고련피 외에, 연꽃잎 추출물을 더 함유할 수 있다.The composition of the present invention may further contain a lotus leaf extract, in addition to a lotus root.
연꽃은 Nelumbo nuficera의 학명으로 불리기도 하며, 노란색 꽃이 피는 다년생 수생 식물로서, 음식 재료로 널리 사용되고 있을 뿐만 아니라 아시아 동부지역 특히 중국에서 다양한 의약재로 사용되고 있다. 구체적으로, 연꽃의 씨앗은 조직 염증, 암 및 나병 치료 그리고 독약 등의 다양한 용도에 응용되고 있다. 또한 연꽃의 배유아는 생체 내(in vivo)에서 급성 염증을 완화시키는 것으로 보고되어 있다. 또한 연꽃잎은 지혈 작용을 가지는 전통 중국 의약품으로 사용되고 있고, 실험동물에서도 과지혈증을 완화시키는 것으로 알려져 있다.The lotus is Nelumbo It is a perennial aquatic plant with yellow flowers and is widely used as a food material. It is also used as a variety of medicines in eastern Asia, especially in China. Specifically, seeds of lotus have been applied to various uses such as tissue inflammation, cancer and leprosy treatment, and poisoning. It has also been reported that lotus infant infants alleviate acute inflammation in vivo. In addition, the petal leaf is used as a traditional Chinese medicine having a hemostatic effect and is known to alleviate hyperlipemia in experimental animals.
본 발명에서 사용되는 고련피 또는 연꽃잎 추출물은 추출방법이 특별히 한정되지는 않으며, 물 또는 유기용매로 추출물을 수득할 수 있다. 본 발명에서 사용하는 유기용매는 에탄올, 메탄올, 부탄올, 에테르, 에틸아세테이트 및 클로로포름으로 이루어진 군에서 선택된 하나 이상일 수 있으며, 또는 이들 유기용매와 물과의 혼합용매를 사용할 수도 있다. 본 발명에서는 한국식물추출물은행에서 구입한 것을 사용하였다.The extraction method is not particularly limited, and the extract can be obtained with water or an organic solvent. The organic solvent used in the present invention may be at least one selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate and chloroform, or a mixed solvent of these organic solvents and water may be used. In the present invention, those purchased from the Korean plant extract bank were used.
상기 방법으로 제조된 고련피 또는 연꽃잎 추출물은 조성물 총 중량에 대하여 1 내지 30중량%의 양으로 함유되는 것이 바람직하다. 추출물의 총량이 1중량% 미만이면 효과가 미미하고, 30중량% 초과이면 안정성에 문제가 생길 수 있다.It is preferable that the spirit or the petiole extract prepared by the above method is contained in an amount of 1 to 30% by weight based on the total weight of the composition. If the total amount of the extract is less than 1% by weight, the effect is insignificant. If the total amount is more than 30% by weight, the stability may be deteriorated.
본 발명의 고련피 추출물을 유효성분으로 함유하는 조성물 및 고련피 추출물과 연꽃잎 추출물을 동시에 함유하는 조성물은 항산화 효과를 갖는다.The composition containing the extract of the present invention as an active ingredient and the composition containing both the extract of the extract of the gruel and the extract of the soft petal leaf have an antioxidative effect.
후술할 실험예 1 및 도 1에서 확인할 수 있는 바와 같이, 상기 항산화 효과는 활성산소종 생성을 억제하는 것을 통하여 달성될 수 있다. 활성산소종(Reactive Oxygen Species, ROS)은 자유 전자를 가진 산소화합물로, 불안정한 상태를 안정시키고자 세포막의 구성성분인 지질단백이나 세포 내 DNA를 공격하여 세포의 파괴 및 자살 등을 일으켜 각종 질환의 발병과 노화를 촉진시키는 원인이 된다. 따라서 활성산소종을 감소시킴으로써 피부 노화를 예방할 수 있다.As can be seen from Experimental Example 1 and FIG. 1 to be described later, the antioxidative effect can be achieved by inhibiting the production of reactive oxygen species. Reactive Oxygen Species (ROS) is an oxygen compound with free electrons. It stabilizes the unstable state and attacks the lipid protein or DNA in the cell membrane, destroying the cells and causing suicide. It causes the onset and aging. Therefore, skin aging can be prevented by reducing active oxygen species.
또한, 후술할 실험예 3 및 도 5에서 확인할 수 있는 바와 같이, 상기 항산화 효과는 항산화 단백질 유전자의 발현을 증가시킴으로써 달성될 수 있다. 상기 항산화 단백질 유전자는 GPX1, 카탈라아제(catalase), Trx1 및 Prdx1를 포함하는 것이나, 이에 한정되는 것은 아니다.In addition, as can be seen from Experimental Example 3 and FIG. 5 to be described later, the antioxidant effect can be achieved by increasing the expression of an antioxidant protein gene. The antioxidant protein gene includes, but is not limited to, GPX1, catalase, Trx1 and Prdx1.
글루타티온 퍼옥시다아제 1(Glutathione peroxidase 1, GPX1)은 인체 내에서 GPX1 유전자에 의해 코딩되는 효소인 글루타티온 퍼옥시다아제(Glutathione peroxidase , GPX)의 여러 종류 중 하나이다. 글루타티온 퍼옥시다아제는 수소 퍼옥시다아제의 해독(detoxification) 에 관여하며 인체내 항산화 효소 중 가장 중요한 효소이다. 본 단백질 서열의 예로서, Hs00829989_Gh를 들 수 있다.Glutathione peroxidase 1 (GPX1) is one of several types of glutathione peroxidase (GPX), an enzyme encoded by the GPX1 gene in the human body. Glutathione peroxidase is involved in the detoxification of hydrogen peroxidase and is the most important enzyme among the antioxidant enzymes in the human body. An example of this protein sequence is Hs00829989_Gh.
카탈라아제(Catalase)는 거의 모든 생물에서 발견되는 공통적인 효소로서 수소 퍼옥시다아제를 물과 산소로 분해하는 것을 촉매시킨다. 본 단백질의 서열의 예로 Hs00156308_m1를 들 수 있다.Catalase is a common enzyme found in almost all organisms and catalyzes the decomposition of hydrogen peroxidase into water and oxygen. An example of the sequence of the present protein is Hs00156308_m1.
티오레독신 1(thioredoxin 1, Trx1)은 산화 및 환원적 스트레스로부터 세포를 보호하는 티오레독신 시스템의 세포질성 티오레독신 아이소엔자임이다. 본 단백질의 서열의 예로서, Hs01555212_g1를 들 수 있다.Thioredoxin 1 (Trx1) is the cytoplasmic thioredoxin isoenzymes of the thioredoxin system that protects cells from oxidative and reductive stress. An example of the sequence of the present protein is Hs01555212_g1.
퍼록시레독신 1(Peroxiredoxin 1, Prdx1)은 인체 내에서 PRDX 1유전자에 의해 코딩되는 단백질이다. 본 단백질 서열의 예로서, Hs00602020_Mh를 들 수 있다.Peroxiredoxin 1 (Prdx1) is a protein encoded by the
또한, 본 발명은 고련피 추출물 및 연꽃잎 추출물을 유효성분으로 함유하는 황사에 의한 피부 유해영향 완화용 조성물을 제공한다. 보다 구체적으로, 본 발명의 조성물은 피부의 정상각질세포(Keratinocyte)에 미치는 유해영향을 완화하는 것일 수 있다.The present invention also provides a composition for alleviating skin harmful effects caused by yellow sand containing an extract of plum blossom and a lotus leaf extract as an active ingredient. More specifically, the composition of the present invention may alleviate the harmful effects on normal keratinocytes of the skin.
후술할 실험예 2 및 도 2 내지 4에서 확인할 수 있는 바와 같이, 고련피 추출물과 연꽃잎 추출물이 동시에 함유될 경우, 연꽃잎 또는 고련피 추출물 각각이 함유된 경우보다 GST, NQO1, hBD3, 각 유전자의 발현이 현저히 증가하는 것을 알 수 있다. GSTT1는 독소를 배출하는 효소이고, NQO1은 독소를 해독하는 효소이며, hBD3는 자연면역인자인 피부항균펩타이드로써, GST, NQO1 또는 hBD3를 포함하는 해독관련효소의 발현이 증가하면 피부 자극을 완화시켜 피부를 보호할 수 있게 된다.As can be seen from Experimental Example 2 and Figs. 2 to 4 to be described later, when the extracts of Goryebyin and Yeast Petal Leaves were contained simultaneously, GST, NQO1, hBD3 and each gene Is significantly increased. GSTT1 is an enzyme that releases toxins, NQO1 is an enzyme that decrypts toxins, and hBD3 is a skin antimicrobial peptide that is a natural immune factor. When the expression of a detoxification-related enzyme including GST, NQO1 or hBD3 increases, The skin can be protected.
글루타티온 에스-트랜스퍼라제(Glutathione S-transferase, GST)는 생체 내에 존재하는 단백질로서 5개 클래스로 나뉜다. 그 중 하나인 글루타티온 에스-트랜스퍼라제 쎄타-1(Glutathione S-transferase theta-1, GSTT1)은 GSTT1 유전자에 의해 코딩되는 효소로서 환원된 글루타티온의 다양한 친전자성 및 소수성 화합물에의 컨져게이션을 촉매시킨다. 단백질 서열의 예로서 Hs00184475_m1를 들 수 있다.Glutathione S-transferase (GST) is a protein in vivo that is divided into five classes. One of them, Glutathione S-transferase theta-1 (GSTT1), catalyses the conjugation of reduced glutathione to a variety of electrophilic and hydrophobic compounds as an enzyme encoded by the GSTT1 gene . An example of a protein sequence is Hs00184475_m1.
퀴논옥시도리덕타아제(quinine oxidoreductase 1, NQ01)는 생체 내에 존재하는 단백질로서 퀴논의 두 전자 환원을 촉매시킨다. 이 효소는 퀴논-매개 발암성에 대해 생체를 보호하고 생체 환원 알킬화제를 활성화시킨다. 본 단백질 서열의 예로서, Hs01045994_m1를 들 수 있다.Quinine oxidoreductase 1 (NQ01) is an in vivo protein that catalyzes the electron reduction of quinone. The enzyme protects the body against quinone-mediated carcinogenesis and activates the body-reducing alkylating agent. An example of this protein sequence is Hs01045994_m1.
인간 베타 디펜신 3(Human Beta Defensin 3, hBD3)는 항원 제시 세포 (antigen presenting cells) 의 이주 및 활성화를 유도하고 면역 증강제 (immune enhancer) 로서 기능한다. 본 단백질의 서열의 예로서, hs00218678_m1를 들 수 있다.Human Beta Defensin 3 (hBD3) induces migration and activation of antigen presenting cells and functions as an immune enhancer. An example of the sequence of the present protein is hs00218678_m1.
본 발명에 따른 조성물은 화장료 조성물, 약학 조성물 또는 건강식품 조성물일 수 있다.The composition according to the present invention may be a cosmetic composition, a pharmaceutical composition or a health food composition.
상기 화장료 조성물은 그 제형에 특별히 한정되지는 않으며, 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징로션, 클렌징폼, 클렌징워터, 팩, 미용액, 파우더, 바디로션, 바디크림, 바디오일, 바디에센스, 바디세정제, 염모제, 헤어토닉, 모발영양화장수, 헤어에센스, 헤어세럼, 스칼프트리트먼트, 헤어트리트먼트, 헤어컨디셔너, 헤어샴푸, 헤어로션, 치약, 구강청정제, 정발제, 양모제, 로션, 연고, 젤, 크림, 패취 또는 분무제 등으로 제형화될 수 있다.The cosmetic composition of the present invention is not particularly limited to the formulations and may be selected from the group consisting of softening agents, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing lotion, cleansing foam, cleansing water, Body Lotion, Body Cream, Body Oil, Body Essence, Body Wash, Hair Dye, Hair Tonic, Hair Nourishment Lotion, Hair Essence, Hair Serum, Scalp Treatment, Hair Treatment, Hair Conditioner, Hair Shampoo, Hair Lotion , Toothpaste, mouthwash, mouthwash, lotion, ointment, gel, cream, patch or spray.
상기 약학 조성물은 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 경구 투여제 또는 비경구 투여제 형태로 제형화할 수 있다.The pharmaceutical composition may further contain a preservative, a stabilizer, a wetting agent or an emulsifying accelerator, a pharmaceutical adjuvant such as a salt and / or a buffer for controlling osmotic pressure, and other therapeutically useful substances, Can be formulated in the form of an administration agent or a parenteral administration agent.
상기 경구 투여제는 예를 들면, 정제, 환제, 경질 및 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 과립제 등이 있으며, 이들 제형은 유효성분 이외에 희석제(예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로즈 및 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및 폴리에틸렌 글리콜)를 함유할 수 있다. 정제는 또한 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로즈, 나트륨 카복시메틸셀룰로즈 및 폴리비닐피롤리딘과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제, 흡수제, 착색제, 향미제, 및 감미제 등의 약제학적 첨가제를 함유할 수 있다. 상기 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.Examples of the oral administration agent include tablets, pills, hard and soft capsules, liquids, suspensions, emulsions, syrups, granules, etc. These formulations may contain, in addition to the active ingredient, a diluent such as lactose, dextrose, Sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (e.g., silica, talc, stearic acid and magnesium or calcium salts thereof and polyethylene glycols). Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally mixed with starch, agar, alginic acid or its sodium salt Such as disintegrants, absorbents, coloring agents, flavoring agents, and sweetening agents. The tablets may be prepared by conventional mixing, granulating or coating methods.
또한, 상기 비경구 투여제는 예를 들어, 피부 외용제일 수 있으며, 로션, 연고, 겔, 크림, 패취 또는 분무제 제형일 수 있으나, 이에 제한되는 것은 아니다.The parenteral administration agent may be, for example, an external preparation for skin, and may be, but not limited to, a lotion, ointment, gel, cream, patch or spray formulation.
상기 건강식품 조성물은 제형이 특별히 한정되지 않으나, 예를 들어, 정제, 과립제, 드링크제, 캬라멜, 다이어트바 등으로 제형화될 수 있다. 각 제형의 건강식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.The health food composition may be formulated into tablets, granules, drinks, caramels, diet bars and the like, although the formulations are not particularly limited. The health food composition of each formulation may be formulated by those skilled in the art without difficulty, depending on the purpose of formulation or use, in addition to the active ingredient, and the synergistic effect may occur when the composition is applied simultaneously with other ingredients .
상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 약물의 1일 투여 용량은 투여하고자 하는 대상의 미만 진행 정도, 발병 시기, 연령, 건강상태, 합병증 등의 다양한 요인에 따라 달라지지만, 성인을 기준으로 할 때 일반적으로는 상기 조성물 1 내지 500mg/kg, 바람직하게는 30 내지 200 mg/kg을 1일 1 내지 2회 분할하여 투여할 수 있으며, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.The dosage of the active ingredient is within the level of those skilled in the art, and the daily dose of the drug depends on various factors such as the degree of progress of the subject to be administered, the age of onset, age, health condition, As a standard, the composition may be administered in an amount of 1 to 500 mg / kg, preferably 30 to 200 mg / kg, once or twice a day, and the dose may be administered by any method within the scope of the present invention .
이하, 하기 실시예에 의하여 본 발명을 더욱 상세하게 설명하고자 한다. 하지만, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 사상과 범위 내에서 여러 가지 변형 또는 수정할 수 있다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are intended to illustrate the present invention and may be modified or modified within the spirit and scope of the present invention.
[ 실험예 1] 사람 각질 세포에서 황사에 의한 활성산소 생성 변화 [ Experimental Example 1] Production of active oxygen by yellow dust in human keratinocytes
사람정상각질피부세포(Human epidermal neonatal keratinocyte cells)는 상용적으로 확보되어 권장하는 방법으로, 론자사(Lonza, Inc. 미국 메릴랜드주 워커스빌(Walkersville) 소재)에서 구입하여 계대배양한 후 CO2 배양기(CO2 incubator)에서 37℃, 5% CO2 조건하에서 세포를 배양하였다. 세포 배양액은 론자사의 지침서에 따라 배양하였다. 500ml의 KBM-2(Clonetics CC-3103) 배지에 KGM-2 불렛 키트(Bullet kit: BPE(Bovine pituitary extract) 2ml, hEGF(human epidermal growth factor) 0.5 ml, 인슐린(Insulin) 0.5 ml, 하이드로코티손(Hydrocortisone) 0.5ml, 트랜스페린(Transferrin) 0.5 ml, 에피네프린(Epinephrine) 0.5 ml, 젠타마이신 설페이트+암포페리신-B(Gentamycin Suflate + Amphofericin-B: GA-1000) 0.5 ml을 첨가하여 사용하였다.Human epidermal neonatal keratinocyte cells were purchased from Lonza (Inc., Walkersville, Maryland, USA) as a commercially available and recommended method, subcultured, and cultured in a CO 2 incubator (CO 2 37 ℃ in the incubator), 5% CO 2 Cells were cultured under conditions. The cell culture was cultured according to the Lonza's guidelines. 2 ml of a bullet kit (BPE (bovine pituitary extract), 0.5 ml of human epidermal growth factor (hEGF), 0.5 ml of insulin, 0.5 ml of hydrocortisone (Clonetics CC-3103) Hydrocortisone (0.5 ml), Transferrin (0.5 ml), Epinephrine (0.5 ml) and Gentamycin Suflate + Amphofericin-B (GA-1000)
사람 각질세포를 배양한 무처리군(대조군)을 준비하였다. 실험군의 경우 사람 각질세포 배양액에, 고련피 추출물 처리 실험군의 경우 10ppm의 고련피 추출물(한국식물추출물은행에서 구입)을 첨가하였고, 연꽃잎 추출물 처리 실험군도 10ppm의 연꽃잎 추출물(한국식물추출물은행에서 구입)을 첨가하였다. 고련피 및 연꽃잎 추출물 동시 처리 실험군의 경우 각각 5ppm의 고련피 및 연꽃잎 추출물 동량을 첨가하여 30분 전처리 후 황사시료 25㎍/ml을 첨가하여 24시간 세포와 함께 배양하였다. 황사시료는 황사기간에 경기도 용인에 위치한 태평양기술연구원 옥상에서 포집하였다. 황사를 25㎍/㎖ 씩 처리하고 24시간 후, 10ml의 인산염 완충액(Phosphate Buffered Saline, PBS)으로 세포를 두 번 세척하고, 2ml의 인산염 완충액에 외부로 생성되는 1mM luminol과 20Units/ml horse-radish peroxidase(HRP)를 넣어 chemiluminescence를 Glomax 20/20 Luminometer를 사용하여 1분 후 측정하였으며, 그 결과를 도 1에 도시하였다.(Control group) in which human keratinocytes were cultured were prepared. In the experimental group, 10 ppm of ginseng extract (purchased from the Korean Plant Extract Bank) was added to the human keratinocyte culture medium, and 10 ppm of the petal leaf extract Purchased) was added. For the simultaneous treatment of extracts of Goryeo pinealis and Kneading leaf extracts, 5ppm of each of the same amount of softwood and soft petal extracts was added, followed by 30 minutes of pretreatment, followed by addition of 25μg / ml of yellow sand samples and incubation with the cells for 24 hours. Yellow sand samples were collected on the rooftop of the Pacific Technology Research Institute located in Yongin, Gyeonggi Province during the DSS period. After 24 hours of treatment with 25 μg / ml of dust, the cells were washed twice with 10 ml of phosphate buffered saline (PBS), and 1 ml of luminol and 20 units / ml horse-radish externally generated in 2 ml of phosphate buffer Peroxidase (HRP) was added and the chemiluminescence was measured after 1 minute using a Glomax 20/20 Luminometer. The results are shown in FIG.
도 1에서 볼 수 있는 바와 같이, 사람정상각질피부세포에서 황사에 의해 증가된 활성산소의 생성을 고련피 추출물 및 연꽃잎 추출물이 억제하며, 특히 고련피 추출물 및 연꽃잎 추출물이 동시에 함유되었을 때 상승효과로 인하여 더욱 현저하게 억제 효과가 나타나는 것을 확인하였다.As can be seen from Fig. 1, the production of active oxygen increased by yellow dust in human normal keratinocyte cells was suppressed by the extracts of Ganoderma lucidum extract and Yeast Petal Leaf. Especially, It was confirmed that the inhibitory effect was more remarkable due to the effect.
[ 실험예 2] 고련피 또는 연꽃잎 추출물 처리시 독소해독 및 배출인자, 자연면역인자인 피부항균펩타이드의 유전자 발현 증가 확인 [ Experimental Example 2] Increase of gene expression of skin antimicrobial peptide, which is a natural immune factor,
사람정상각질피부세포(Human epidermal neonatal keratinocyte cells)는 상용적으로 확보되어 권장하는 방법으로, 론자사에서 구입하여 계대배양한 후 CO2 배양기(CO2 incubator)에서, 37℃, 5% CO2 조건하에서 세포를 배양하였다. 세포 배양액은 론자사의 지침서에 따라 배양하였다. 500ml의 KBM-2(Clonetics CC-3103) 배지에 KGM-2 불렛 키트(Bullet kit: BPE(Bovine pituitary extract) 2ml, hEGF(human epidermal growth factor) 0.5 ml, 인슐린(Insulin) 0.5 ml, 하이드로코티손(Hydrocortisone) 0.5ml, 트랜스페린(Transferrin) 0.5 ml, 에피네프린(Epinephrine) 0.5 ml, 젠타마이신 설페이트+암포페리신-B(Gentamycin Suflate + Amphofericin-B: GA-1000) 0.5 ml을 첨가하여 사용하였다.Human epidermal neonatal keratinocyte cells are commercially available and recommended by the company. They are purchased from Ronji Co., Ltd., subcultured, and cultured in a CO 2 incubator (CO 2 In the incubator), 37 ℃, 5
사람 각질세포를 배양한 무처리군(대조군)을 준비하였다. 실험군의 경우 사람 각질세포 배양액에, 고련피 추출물 처리 실험군의 경우 10ppm의 고련피 추출물(한국식물추출물은행에서 구입)을 첨가하였고, 연꽃잎 추출물 처리 실험군도 10ppm의 연꽃잎 추출물(한국식물추출물은행에서 구입)을 첨가하였다. 고련피 및 연꽃잎 추출물 동시 처리 실험군의 경우 각각 5ppm의 고련피 및 연꽃잎 추출물을 동량으로 첨가하여 30분 전처리 후 황사시료 25㎍/ml을 첨가하여 24시간 세포와 함께 배양하였다. 고련피 또는 연꽃잎 추출물, 황사 처리 24시간 후, 10ml의 인산염 완충액으로 세포를 두 번 세척하고, 트라이졸(인비트로젠사)을 이용하여 세포 내의 전체 RNA(total RNA)를 분리하였다. 분리된 RNA를 키아젠사의 RNA 키트를 사용하여, 한번 더 정제한 후, 애질런트사의 바이오어낼라이저 2100 모델 기기를 이용하여, RNA의 질(quality)을 확인하였다. 인비트로젠사의 역전사키트(Superscript Reverse Transcriptase (RT) II kit)를 이용하여 상기 분리된 RNA로부터 cDNA를 합성하였고, 이를 실시간역전사중합효소연쇄반응(real time-reverse transcription polymerase chain reaction, Q-RT-PCR)으로 정량적으로 분석하였다. GSTT1(Hs00184475_m1), NQO1(Hs01045994_m1), hBD3(hs00218678_m1)의 발현 패턴 변화는 어플라이드 바이오시스템사의 택맨 유전자발현시스템(TaqMan®geneexpressionassaykit)을 이용하여 평가하였으며, 그 결과를 도 2 내지 4에 도시하였다.(Control group) in which human keratinocytes were cultured were prepared. In the experimental group, 10 ppm of ginseng extract (purchased from the Korean Plant Extract Bank) was added to the human keratinocyte culture medium, and 10 ppm of the petal leaf extract Purchased) was added. For the simultaneous treatment of extracts of Ganoderma lucidum and Kneading leaf, 5ppm of each of the extracts of Ganoderma lucidum and Yeast Petal were added in the same amount. After 30 minutes of pretreatment, 25μg / ml of yellow dust was added and cultured for 24 hours. Twenty four hours after the treatment, the cells were washed twice with 10 ml of phosphate buffer, and the total RNA (total RNA) in the cells was isolated using Triazole (Invitrogen). The separated RNA was purified once more using a Qiagen RNA kit, and the quality of the RNA was confirmed using Agilent's BioAdmin 2100 model device. CDNA was synthesized from the separated RNAs using a Superscript Reverse Transcriptase (RT) II kit from Invitrogen. Real-time reverse transcription polymerase chain reaction (Q-RT- PCR). The expression patterns of GSTT1 (Hs00184475_m1), NQO1 (Hs01045994_m1) and hBD3 (hs00218678_m1) were evaluated using a TaqMan gene expression system (TaqMan® gene expression system) from Applied Biosystems. The results are shown in FIGS.
도 2 내지 4에서 볼 수 있는 바와 같이, 고련피 및 연꽃잎 추출물이 사람정상각질피부세포에서, 독성물질을 해독하는 NQO1[도 2], 자연면역인자인 피부항균펩타이드 hBD3[도 3] 및 독소를 배출하는 효소인 GSTT1[도 4]의 유전자 발현양을 증가시킴을 확인하였다. 이러한 효과는 고련피 및 연꽃잎 추출물을 혼합 처리시 더욱 현저하게 효과가 있음을 알 수 있었다.As can be seen from Figs. 2 to 4, in the normal normal keratinocyte cells, the extract of psyllium and soft petals extracts NQO1 [Fig. 2] which decodes a toxic substance, a skin antimicrobial peptide hBD3 [Fig. 3] The amount of gene expression of GSTT1 (Fig. 4), which is an enzyme that excretes GSTT1, is increased. These effects were found to be more remarkable when mixed with sesame seeds and soft petal extracts.
따라서, 고련피 또는 연꽃잎 추출물의 혼합 처리시 독소해독, 배출 및 자연면역인자의 발현 또한 상승효과로 인하여 증가시키는 효과가 있음을 알 수 있었다.Therefore, it was found that toxin detoxification, excretion, and expression of natural immunity factors were also increased by the synergistic effect when the mixture of sesame oil or soft petal leaf extract was mixed.
[ 실험예 3] 고련피와 연꽃잎 추출물 처리시 항산화 단백질 유전자 발현 증가 확인 [ Experimental Example 3] Expression of Antioxidant Protein Gene Expression in the Treatment of Goryeo Blood and Soft Petal Leaves Extract
사람정상각질피부세포(Human epidermal neonatal keratinocyte cells)는 상용적으로 확보되어 권장하는 방법으로, 론자사에서 구입하여 계대배양한 후 CO2 배양기(CO2 incubator)에서, 37℃, 5% CO2 조건하에서 세포를 배양하였다. 세포 배양액은 론자사의 지침서에 따라 배양하였다. 500ml의 KBM-2(Clonetics CC-3103) 배지에 KGM-2 불렛 키트(Bullet kit: BPE(Bovine pituitary extract) 2ml, hEGF(human epidermal growth factor) 0.5 ml, 인슐린(Insulin) 0.5 ml, 하이드로코티손(Hydrocortisone) 0.5ml, 트랜스페린(Transferrin) 0.5 ml, 에피네프린(Epinephrine) 0.5 ml, 젠타마이신 설페이트+암포페리신-B(Gentamycin Suflate + Amphofericin-B: GA-1000) 0.5 ml을 첨가하여 사용하였다.Human epidermal neonatal keratinocyte cells are commercially available and recommended by the company. They are purchased from Ronji Co., Ltd., subcultured, and cultured in a CO 2 incubator (CO 2 In the incubator), 37 ℃, 5
사람 각질세포를 배양한 무처리군(대조군)을 준비하였다. 실험군의 경우 사람 각질세포 배양액에, 고련피 추출물 처리 실험군의 경우 10ppm의 고련피 추출물(한국식물추출물은행에서 구입)을 첨가하였고, 연꽃잎 추출물 처리 실험군도 10ppm의 연꽃잎 추출물(한국식물추출물은행에서 구입)을 첨가하였다. 고련피 및 연꽃잎 추출물 동시 처리 실험군의 경우 각각 5ppm의 고련피 및 연꽃잎 추출물을 동량으로 첨가하여 24시간 세포와 함께 배양하였다. 물질 처리 24시간 후, 10ml의 인산염 완충액으로 세포를 두 번 세척하고, 트라이졸(인비트로젠사)을 이용하여 세포 내의 전체 RNA(total RNA)를 분리하였다. 분리된 RNA를 키아젠사의 RNA 키트를 사용하여, 한번 더 정제한 후, 애질런트사의 바이오어낼라이저 2100 모델 기기를 이용하여, RNA의 질(quality)을 확인하였다. 인비트로젠사의 역전사키트(Superscript Reverse Transcriptase (RT) II kit)를 이용하여 상기 분리된 RNA로부터 cDNA를 합성하였고, 이를 실시간역전사중합효소연쇄반응(real time-reverse transcription polymerase chain reaction, Q-RT-PCR)으로 정량적으로 분석하였다. GPX1(Hs00829989_gH), catalase(Hs00156308_m1), Trx1(Hs01555212_g1), PRDX1(Hs00602020_mH)의 발현 패턴 변화는 어플라이드 바이오시스템사의 택맨 유전자발현시스템(TaqMan®geneexpressionassaykit)을 이용하여 평가하였다.(Control group) in which human keratinocytes were cultured were prepared. In the experimental group, 10 ppm of ginseng extract (purchased from the Korean Plant Extract Bank) was added to the human keratinocyte culture medium, and 10 ppm of the petal leaf extract Purchased) was added. For the simultaneous treatment of sclerotin and soft petal extracts, 5ppm of spicy and leaf petal extracts were added in the same amount and cultured for 24 hours. After 24 hours of treatment of the material, the cells were washed twice with 10 ml of phosphate buffer, and total RNA (total RNA) in the cells was isolated using a triazole (Invitrogen). The separated RNA was purified once more using a Qiagen RNA kit, and the quality of the RNA was confirmed using Agilent's BioAdmin 2100 model device. CDNA was synthesized from the separated RNAs using a Superscript Reverse Transcriptase (RT) II kit from Invitrogen. Real-time reverse transcription polymerase chain reaction (Q-RT- PCR). Changes in the expression patterns of GPX1 (Hs00829989_gH), catalase (Hs00156308_m1), Trx1 (Hs01555212_g1) and PRDX1 (Hs00602020_mH) were evaluated using a TaqMan gene expression system (Applied Biosystems, TaqMan® geneexpression assay kit).
사람정상각질피부세포에서 활성산소를 제거하는 항산화 효소인 GPX1, catalase, Trx1, Prdx1의 상대적 발현량이 고련피 추출물의 경우 각각 약 2.5, 2.0, 1.9, 1.9였고, 연꽃잎 추출물의 경우 각각 약 1.9, 1.7, 1.6, 1.7이었다. 고련피와 연꽃잎 추출물을 함께 처리하는 경우는 도 5에 도시한 바와 같이, GPX1, catalase, Trx1, Prdx1 각각 약 3.0, 2.43, 2.48, 2.4로, 가장 발현량이 높은 것을 알 수 있었다.The relative expression levels of GPX1, catalase, Trx1 and Prdx1, which are antioxidative enzymes that remove reactive oxygen species in normal human keratinocytes, were about 2.5, 2.0, 1.9 and 1.9, respectively. 1.7, 1.6 and 1.7, respectively. As shown in FIG. 5, GPX1, catalase, Trx1 and Prdx1 were found to have the highest expression levels of about 3.0, 2.43, 2.48 and 2.4, respectively, in the case of treatment with sesame seeds and soft petiole extracts.
따라서, 이를 통해 항산화 효소의 발현이 고련피 추출물 단독 처리시 증가할 뿐 아니라, 고련피 및 연꽃잎 추출물 동시 처리시에는 더욱 증가하여 유효한 효과를 가짐을 알 수 있었다.Therefore, it was found that the antioxidant enzyme expression was increased not only in the treatment of Goryeong Bark extract but also in the simultaneous treatment of Goryeon bloom and soft petal leaf extract.
본 발명의 고련피 및 연꽃잎 추출물을 함유하는 조성물의 제형예를 하기에서 설명하지만, 본 발명의 조성물이 이 예로만 한정되는 것은 아니다.Formulation examples of the composition containing the sprouted and soft petal extract of the present invention are described below, but the composition of the present invention is not limited to this example.
[ 제형예 1] 로션형 제형 [ Formulation Example 1] Lotion-type formulation
고련피 및 연꽃잎 추출물 3.00Spicy bloom and soft petal extract 3.00
L-아스코르빈산-2-인산마그네슘염 1.00L-ascorbic acid-2-phosphate magnesium salt 1.00
수용성 콜라겐 (1% 수용액) 1.00Water soluble collagen (1% aqueous solution) 1.00
시트르산나트륨 0.10Sodium citrate 0.10
시트르산 0.05Citric acid 0.05
감초 엑기스 0.20Licorice extract 0.20
1,3-부틸렌글리콜 3.001,3-butylene glycol 3.00
정제수 잔량Purified water balance
(단위: 중량%)(Unit: wt%)
[ 제형예 2] 크림형 제제 [ Formulation Example 2]
고련피 및 연꽃잎 추출물 1.00Spicy bloom and soft petal extract 1.00
폴리에틸렌글리콜모노스테아레이트 2.00Polyethylene glycol monostearate 2.00
자기유화형 모노스테아르산글리세린 5.00Self emulsifying monostearate glycerin 5.00
세틸알코올 4.00Cetyl alcohol 4.00
스쿠알렌 6.00Squalane 6.00
트리2-에틸헥산글리세릴 6.00Tri-2-ethylhexane glyceryl 6.00
스핑고당지질 1.00Sphingo glycolipid 1.00
1,3-부틸렌글리콜 7.001,3-butylene glycol 7.00
정제수 잔량Purified water balance
(단위: 중량%)(Unit: wt%)
[ 제형예 3] 팩형 제제 [ Formulation Example 3] Packed preparation
고련피 및 연꽃잎 추출물 5.00Spicy bloom and soft petal extract 5.00
폴리비닐알코올 13.00Polyvinyl alcohol 13.00
L-아스코르빈산-2-인산마그네슘염 1.00L-ascorbic acid-2-phosphate magnesium salt 1.00
라우로일히드록시프롤린 1.00Lauroylhydroxyproline 1.00
수용성 콜라겐 (1% 수용액) 2.00Water soluble collagen (1% aqueous solution) 2.00
1,3-부틸렌글리콜 3.001,3-butylene glycol 3.00
에탄올 5.00Ethanol 5.00
정제수 잔량Purified water balance
(단위: 중량%)(Unit: wt%)
[ 제형예 4] 미용액형 제제 [ Formulation Example 4] Cosmetic liquid preparations
고련피 및 연꽃잎 추출물 2.00Spicy bloom and soft petal extract 2.00
히드록시에틸렌셀룰로오스 (2% 수용액) 12.00Hydroxyethylene Cellulose (2% aqueous solution) 12.00
크산탄검 (2% 수용액) 2.00Xanthan gum (2% aqueous solution) 2.00
1,3-부틸렌글리콜 6.001,3-butylene glycol 6.00
진한 글리세린 4.00Dark glycerin 4.00
히알루론산나트륨 (1% 수용액) 5.00Sodium hyaluronate (1% aqueous solution) 5.00
정제수 잔량Purified water balance
(단위: 중량%)(Unit: wt%)
Claims (9)
상기 조성물은 활성산소종 생성을 억제함을 특징으로 하는 조성물.3. The method of claim 2,
Wherein said composition inhibits production of reactive oxygen species.
상기 조성물은 항산화 단백질 유전자의 발현을 증가시킴을 특징으로 하는 조성물.3. The method of claim 2,
Wherein said composition increases the expression of an antioxidant protein gene.
상기 항산화 단백질 유전자는 GPX1, 카탈라아제(catalase), Trx1 및 Prdx1를 포함하는 것인 조성물.5. The method of claim 4,
Wherein the antioxidant protein gene comprises GPXl, catalase, Trxl, and Prdxl.
상기 황사에 의한 피부 유해영향 완화는 황사에 의한 활성산소 생성 억제, 황사에 의한 피부 독소의 배출 또는 해독, 또는 피부 항균 펩타이드 촉진을 통한 피부 보호인 조성물.A composition for relieving skin harmful effects caused by yellow sand containing an extract of Oriental peel and a lotus leaf extract as an active ingredient,
The composition of the present invention is a composition for preventing skin damage caused by yellow dust, for inhibiting the formation of active oxygen by yellow dust, for discharging or detoxifying skin toxins caused by yellow dust, or for promoting skin antimicrobial peptides.
상기 조성물은 GST, NQO1 또는 hBD3의 발현을 증가시킴을 특징으로 하는 조성물.The method according to claim 6,
Wherein said composition increases the expression of GST, NQO1 or hBD3.
상기 조성물은 피부의 정상각질세포(Keratinocyte)에 미치는 유해영향을 완화하는 것을 특징으로 하는 조성물.8. The method according to any one of claims 2 to 7,
Wherein the composition alleviates adverse effects on keratinocytes of the skin.
상기 추출물의 총량은 조성물 총 중량에 대하여 1 내지 30 중량%인 것인 조성물.8. The method according to any one of claims 2 to 7,
Wherein the total amount of the extract is from 1 to 30% by weight based on the total weight of the composition.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2011/000010 WO2012093738A1 (en) | 2011-01-03 | 2011-01-03 | Composition for combating oxidation and alleviating detrimental effects on skin caused by asian dust |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130132508A KR20130132508A (en) | 2013-12-04 |
| KR101637973B1 true KR101637973B1 (en) | 2016-07-11 |
Family
ID=46457585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137016899A KR101637973B1 (en) | 2011-01-03 | 2011-01-03 | Composition for combating oxidation and alleviating detrimental effects on skin caused by asian dust |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR101637973B1 (en) |
| CN (1) | CN103415299B (en) |
| SG (1) | SG191808A1 (en) |
| WO (1) | WO2012093738A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102041485B1 (en) * | 2017-09-25 | 2019-11-06 | 제주대학교 산학협력단 | Cosmetic composition comprising 3,4-dicaffeoylquinic acid for protecting skin against reactive oxygen species, ultraviolet ray or particulate matter |
| KR102040230B1 (en) * | 2017-09-25 | 2019-11-04 | 제주대학교 산학협력단 | Cosmetic composition comprising purpurogallin for protecting skin against reactive oxygen species, ultraviolet ray or particulate matter |
| KR102091923B1 (en) | 2018-03-15 | 2020-03-20 | 에스케이바이오랜드 주식회사 | Cosmetic composition comprising extract of Spirodela polyrhiza for improvement of skin damage or skin-protection |
| KR102257477B1 (en) * | 2019-07-25 | 2021-05-31 | 주식회사 더가든오브내추럴솔루션 | Cosmetic composition having Anti-pollution effect comprising Lotus leaf extracts as an effective component |
| CN112956569A (en) * | 2021-03-17 | 2021-06-15 | 国健药业(深圳)集团有限公司 | Polygonatum odoratum beauty tea and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060100115A (en) * | 2005-03-16 | 2006-09-20 | 주식회사 해피어스화장품 | Cosmetic composition including nelumbo nucifera extract with antioxidant effect |
| KR100815873B1 (en) * | 2007-04-18 | 2008-03-28 | 대구한의대학교산학협력단 | A cosmetic composition comprising an extract of ailanthus altissima having antioxidative effect |
| KR101116447B1 (en) * | 2009-05-29 | 2012-03-07 | (주)아모레퍼시픽 | Cosmetic composition for activation of skin cell dynamics |
-
2011
- 2011-01-03 KR KR1020137016899A patent/KR101637973B1/en active IP Right Grant
- 2011-01-03 SG SG2013051024A patent/SG191808A1/en unknown
- 2011-01-03 CN CN201180068574.7A patent/CN103415299B/en active Active
- 2011-01-03 WO PCT/KR2011/000010 patent/WO2012093738A1/en active Application Filing
Non-Patent Citations (1)
| Title |
|---|
| HEO, CHAN et al., 'Antioxidative Activities of 60 Plnt extract', The Journal of applied Pharmacology, Vol.11, pp.196-199, 2003* |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103415299A (en) | 2013-11-27 |
| SG191808A1 (en) | 2013-08-30 |
| WO2012093738A1 (en) | 2012-07-12 |
| CN103415299B (en) | 2017-02-08 |
| KR20130132508A (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baliga et al. | Chemistry and medicinal properties of the Bakul (Mimusops elengi Linn): A review | |
| JP5361820B2 (en) | Glutathione enhancing composition | |
| Amudhan et al. | A review on phytochemical and pharmacological potential of Areca catechu L. seed | |
| Jorge et al. | Insulinomimetic effects of kaempferitrin on glycaemia and on 14C-glucose uptake in rat soleus muscle | |
| KR101059471B1 (en) | Cosmetic composition for skin aging | |
| KR101637973B1 (en) | Composition for combating oxidation and alleviating detrimental effects on skin caused by asian dust | |
| Singh et al. | Protective role of Terminalia Chebula in streptozotocin-induced diabetic mice for wound healing activity | |
| KR20200018879A (en) | Natural cosmetic formulation with excellent effect for skin-microbiome homeostasis and anti-inflammation | |
| Panda et al. | Antiulcer activity of Garcinia indica fruit rind (kokum berry) in rats | |
| Rani et al. | Molsari (Mimusops elengi Linn.): A boon drug of traditional medicine | |
| Mohammadi et al. | Pomegranate: A review of the heavenly healer’s past, present, and future | |
| KR102150927B1 (en) | Cosmetic and pharmaceutical compositin comprising sasa quelpaertensis extract and urea | |
| KR102087188B1 (en) | Composition comprising Prunus mume flower extract for caring damages of skin cells by microdust | |
| KR20210091430A (en) | Cosmetic composition containing natural complex extracts as active ingredient | |
| KR20070023845A (en) | Cosmetic composition comprising extracts of ginkgo biloba l. and process of manufacturing their products | |
| KR101601865B1 (en) | Method for screening harmful responses of skin by pollen house dust mite or yellow sand dust and the composition for skin external application controlling the responses | |
| KR101702621B1 (en) | Anti-inflammatory agent containing phlox subulata extract | |
| KR100589667B1 (en) | Compositions of cosmetics for atopy skin containing specific oriental herbal extracts | |
| JP6545856B2 (en) | Composition for treating wounds, comprising a venom extract or fraction thereof, and method of treating wounds in an individual | |
| KR20220070122A (en) | A composition for skin anti-pollution containing a daughter-in-law navel extract | |
| KR102090133B1 (en) | Composition comprising Hibiscus syriacus L. extract for caring damages of skin cells by microdust | |
| KR20170065187A (en) | Cosmetic composition for improving acne containing tea-tree leaves complex extract | |
| KR101769123B1 (en) | Cosmetic composition containing natural complex extract for improving atopic dermatitis | |
| KR20140145268A (en) | Cosmetic composition containing compound for pore convergence and acne suppression. | |
| KR102478898B1 (en) | Saururus chinensis extract using oriental processing and its use for external skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20190701 Year of fee payment: 4 |